Tolera

P.O. Box 970
Portage, MI 49081-0970
Phone: (269) 585-2100
Email: info@tolera.com

About Us

Tolera Therapeutics is a privately held biotechnology company comprised of experienced life science investors, executive leadership, translational medicine experts, clinical trialists, immunologists and scientific collaborators. At Tolera, we are dedicated to bringing better targeted, more effective, and well tolerated therapeutics to market to improve the lives of patients suffering from a broad spectrum of autoimmune and immune-mediated diseases. We are accomplishing our mission using a novel, proprietary non-depleting methodology targeting the human alpha-beta T-cell receptor (αβTCR). Our proprietary approach appears to render pathologic T-cells inert and through a unique signaling pathway expands regulatory T-cells, which are critical for long term disease control.

To date we have elucidated much of the underlying mechanism of action of Tolera's αβTCR targeting technology and demonstrated human proof-of-concept by way of a Phase 2 clinical trial of our first generation anti-αβTCR antibody (TOL101) in short course immune induction therapy in solid organ transplantation (SOTx). Having successfully negotiated a special protocol assessment (SPA) with the FDA for Phase 3 clinical testing of TOL101 in renal transplant patients, we are now currently seeking a qualified licensee to further develop and effectively commercialize this breakthrough therapeutic candidate for SOTx and graft versus host disease (GvHD). Meanwhile, we are concentrating our internal efforts and resources on engineering and formulating second generation therapeutics focused on autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, systemic lupus, and inflammatory bowel disease.

Board of Directors

  • Suzette Dutch, Chair
  • Ashleigh Palmer, CEO
  • Douglas R. Morton, Jr. Ph.D
  • Donald R. Parfet
  • Mark Olesnavage